Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors

Cancer Research

Volumn 70, Issue 1, 2010, Pages 319-328

  Wang, Liewei ^a   Ellsworth, Katarzyna A ^a   Moon, Irene ^a   Pelleymounter, Linda L ^a   Eckloff, Bruce W ^a   Martin, Yvette N ^a   Fridley, Brooke L ^b   Jenkins, Gregory D ^b   Batzler, Anthony ^b   Suman, Vera J ^b   Ravi, Saranya ^a   Dixon, J Michael ^c,d   Miller, William R ^c   Wieben, Eric D ^a   Buzdar, Aman ^e   Weinshilboum, Richard M ^a   Ingle, James N ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d Breakthrough Research Unit   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE; CYTOCHROME P450; ESTRADIOL; EXEMESTANE; GENOMIC DNA; LETROZOLE;

ADJUVANT THERAPY; ARTICLE; BREAST; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; EARLY CANCER; ESTRADIOL BLOOD LEVEL; EXON; FEMALE; FOLLOW UP; GEL MOBILITY SHIFT ASSAY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; GERM LINE GENE THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTRADIOL; FEMALE; GENOTYPE; HUMANS; NEOADJUVANT THERAPY; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 75149159605     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3224     Document Type: Article

References (33)

1. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20: 751-7.
2. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93.
3. Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol 2005;95:113-9.
4. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Cancer Res 2009;69:66S.
5. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001;79:93-102.
6. Watanabe J, Harada N, Suemasu K, Higashi Y, Gotoh O, Kawajiri K. Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. Pharmacogenetics 1997;7: 419-24.
7. Kristensen VN, Harada N, Yoshimura N, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000;19: 1329-33.
8. Probst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6:165-73.
9. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999;79:456-63.
10. Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-10.
11. Bershtein LM, Imianitov EN, Suspitsyn EN, et al. A polymorphism study of the CYP19 gene in endometrial cancer patients. Vopr Onkol 2000;46:302-5.
12. Baxter SW, Choong DY, Eccles DM, Campbell IG. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001;22:347-9.
13. Masi L, Becherini L, Gennari L, et al. Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J Clin Endocrinol Metab 2001;86: 2263-9.
14. Miyoshi Y, Ando A, Hasegawa S, et al. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 2003;39:2531-7.
15. Thyagarajan B, Brott M, Mink P, et al. CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Cancer Lett 2004;207:183-9.
16. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
17. Lloveras B, Monzo M, Colomer R, et al. Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. Am Soc Clin Oncol Annu Meet Proc (Post-Meet Ed) 2004;22:507.
18. Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65: 11071-82.
19. Brueggemeier RW, Richards JA, Joomprabutra S, Bhat AS, Whetstone JL. Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. J Steroid Biochem Mol Biol 2001;79:75-84.
20. Hahn EF, Fishman J. Immunological probe of estrogen biosynthesis. Evidence for the 2β-hydroxylative pathway in aromatization of androgens. J Biol Chem 1984;259:1689-94.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976;72:248-154.
22. Peter H, Westfall RDT, Rom D, Wolfinger RD, Hochberg Y. Multiple comparisons and multiple tests: using the SAS system. Cary (NC): SAS Institute; 2000.
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
24. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
25. Agresti A. Categorical data analysis. Hoboken (NJ): John Wiley & Sons, Inc.; 2002.
26. Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika 1974;61: 439-47.
27. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101-8.
28. Kinoshita Y, Chen S. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor α. Cancer Res 2003;63:3546-55.
29. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76: 27-36.
30. Ingle JN. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res 2005;11:900-5s.
31. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-55.
32. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
33. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92